Novo Nordisk A/S NVO

Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.

Bagsværd, Denmark, 12 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme init

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.

Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook. The shares fell anyway, with investors fixated on pricing pressure and the quality of the beat. Then, at a strategy day in London a few weeks ago, management said it aims to grow revenue through 2030 at roughly the […]

Citi Research has lowered its price target for Danish pharmaceutical company Novo Nordisk (NYSE:NVO) to DKK 296 from DKK 310, citing limited opportunities for operating margin expansion through 2030 despite improving expectations for sales of its oral obesity treatment, Wegovy. The investment bank maintained its “neutral” rating on the stock following Novo Nordisk’s recent Capital Markets Day, where management indicated that profit margins were expected to remain “broadly stable” over the coming

Novo Nordisk (CPSE:NOVO B) reported an FDA review update for haemophilia A therapy denecimig, including manufacturing related feedback, in October 2026. The pharmaceutical group presented new CagriSema data on brain and metabolic pathway effects in obesity and diabetes at EASD 2026. Researchers also shared real-world evidence at EASD 2026 comparing clinical outcomes for semaglutide with tirzepatide in everyday practice. Denecimig’s FDA review update and the fresh CagriSema and semaglutide...

Investing.com -- Citi Research cut its price target on Danish drugmaker Novo Nordisk to 296 Danish crowns from 310 because the company’s guidance for "broadly stable" margins through 2030 leaves little room for margin growth, Citi analysts said.